Targeted Methotrexate Treatment in Cesarean Scar Pregnancy: A Case Report and Literature Review
Case Reports in Obstetrics and Gynecology · 2026-01 · 2026 (1)
DOI: 10.1155/crog/4653003 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Obstetrics and Gynecology, online erschienen am 13.11.2026. Verfasst von Marta Adamczyk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Collegium Medicum Cardinal Stefan Wyszyński University Warsaw Poland. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cesarean scar pregnancy (CSP) represents a rare form of ectopic pregnancy, though its incidence is expected to rise in countries with rising rates of deliveries by cesarean section (CS). Delayed diagnosis and treatment can result in uterine rupture and hemorrhage. Diagnosis is based on transvaginal ultrasonography (TVUS). No standardized treatment protocol for CSP has been established; however, local ultrasound‐guided methotrexate (MTX) injection into the gestational sac (GS) is widely recognized as a highly effective therapy. Case Report A 38‐year‐old woman with a history of CS 2 years prior was admitted to the hospital due to moderately heavy vaginal bleeding that had started 4 days before. Her general condition was assessed as stable. The last menstrual period occurred 6 weeks and 2 days earlier. A β ‐hCG test performed on presentation showed a level of 10,775 mIU/mL. TVUS revealed a GS measuring 8.6 mm located within the CS scar, containing a yolk sac and an embryo with a CRL of 2.8 mm. Cardiac activity had not been detected. A diagnosis of CSP was made. Other laboratory tests showed no abnormalities. On the following day, the β ‐hCG level had increased to 13,001 mIU/mL. Under TVUS guidance, 80 mg of MTX was injected into the GS. Following days showed a gradual decline in β ‐hCG levels, reaching 927.77 mIU/mL on the third day postprocedure. A follow‐up TVUS revealed no visible GS. The patient remained in stable condition and was discharged from the hospital. On Day 10 postprocedure, the β ‐hCG level had decreased to 62.04 mIU/mL. Aside from mild uterine bleeding, the patient reported no other complaints.
Conclusions
In the presented case, early detection followed by timely ultrasound‐guided MTX injection into the GS achieved complete resolution without requiring additional interventions, highlighting its potential as a safe and effective conservative approach when CSP is diagnosed early.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Collegium Medicum Cardinal Stefan Wyszyński University Warsaw Poland.
- Department of Obstetrics and Gynecology Międzylesie Specialist Hospital Warsaw Poland.
- Trade Union of Pharmacy Workers (ZZPF) Warsaw Poland.
ORCID-Profile: Marta Adamczyk, Aneta Zwierzchowska, Piotr Merks
Zitieren
APA
Adamczyk, M., Limowska, H., Zwierzchowska, A., Merks, P., & Barcz, E. (2026). Targeted Methotrexate Treatment in Cesarean Scar Pregnancy: A Case Report and Literature Review. Case Reports in Obstetrics and Gynecology, 2026(1). https://doi.org/10.1155/crog/4653003
Vancouver
Adamczyk M, Limowska H, Zwierzchowska A, Merks P, Barcz E. Targeted Methotrexate Treatment in Cesarean Scar Pregnancy: A Case Report and Literature Review. Case Reports in Obstetrics and Gynecology. 2026;2026(1). doi:10.1155/crog/4653003
BibTeX
@article{Adamczyk2026,
author = {Adamczyk, Marta and Limowska, Helena and Zwierzchowska, Aneta and Merks, Piotr and Barcz, Ewa},
title = {Targeted Methotrexate Treatment in Cesarean Scar Pregnancy: A Case Report and Literature Review},
journal = {Case Reports in Obstetrics and Gynecology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crog/4653003}
}
EUVIMED